Product	Company	Indication	Approval Date
Anerem (remimazolam besilate)	Mundipharma	General anesthesia	23 January 2020
Beovu Kit (brolucizumab)	Novartis	Age-related macular degeneration associated with subfoveal choroidal neovascularization	25 March 2020
Bevespi Aerosphere (glycopyrronium bromide/formoterol/fumarate hydrate)	AstraZeneca	Chronic obstructive pulmonary disease	18 June 2019
Breztri Aerosphere (budesonide/glycopyrronium bromide/formoterol fumarate hydrate)	AstraZeneca	Chronic obstructive pulmonary disease	18 June 2019
Brineura (cerliponase alfa)	BioMarin	Neuronal ceroid lipofuscinosis type 2 (orphan)	20 September 209
Cabometyx (cabozantinib malate)	Takeda	Unresectable metastatic renal cell carcinoma	25 March 2020
Coralan (ivabradine HCl)	Ono	Chronic heart failure with sinus rhythm and resting heartrate of 75bpm or greater in patients receiving standard treatments including beta-blocker	20 September 2019
Corectim (delgocitinib)	Japan Tobacco	Atopic dermatitis	23 January 2020
Crysvita (burosumab)	Kyowa Kirin	FGF23-related hypophosphatemic rickets/osteomalacia (orphan)	20 September 2019
Dayvigo (lemborexant)	Eisai	Insomnia	23 January 2020
Defitelio (defibrotide Na)	Nippon Shinyaku	Sinusoidal obstruction syndrome, hepatic veno-occlusive disease (orphan)	18 June 2019
Enhertu (trastuzumab deruxtecan)	Daiichi Sankyo	Unresectable/recurrent HER2-positive breast cancer after previous chemotherapy (conditional early approval)	25 March 2020
Equifina (safinamide mesylate)	Meiji Seika Pharma	Wearing off in Parkinson’s with levodopa drugs	20 September 2019
Esperoct (turoctocog alfa pegol)	Novo Nordisk	Factor VIII deficiency	20 September 2019
Evrenzo (roxadustat)	Astellas	Renal anemia in dialysis patients	20 September 2019
Lasvic (lascufloxacin HCl)	Kyorin Pharma	Broad-spectrum antibiotic	20 September 2019
Latuda (lurasidone)	Sumitomo Dainippon Pharma	Schizophrenia, improvement of depressive symptoms in bipolar disorder	25 March 2020
Lokelma (sodium zirconium cyclosilicate hydrate)	AstraZeneca	Hyperkalemia	25 March 2020
Melatobel (melatonin)	Nobelpharma	Difficulty falling asleep associated with pediatric neurodevelopmental disorder	25 March 2020
Noxafil (posaconazole)	MSD	Deep mycosis prophylaxis in hematopoietic stem cell transplants or decreased neutrophils in hematologic malignancies, various mycoses	23 January 2020
Nubeqa (darolutamide)	Bayer	Non-metastatic castration-resistant prostate cancer	23 January 2020
Onpattro (patisiran Na)	Alnylam	Transthyretin familial amyloid polyneuropathy (orphan)	18 June 2019
Pifeltro (doravirine)	MSD	HIV-1	14 January 2020
Portrazza (necitumumab)	Eli Lilly	Unresectable advanced/recurrent squamous NSCLC	18 June 2019
RInvoq (upadacitinib hydrate)	AbbVie	Second-line rheumatoid arthritis (including prevention of structural joint damage)	23 January 2020
Steboronine (borofalan 10B)	Stella Pharma	Locally unresectable recurrent or unresectable advanced head and neck cancer (sakigake)	25 March 2020
Tepmetko (tepotinib)	Merck Biopharma	Unresectable advanced/recurrent MET exon 14 skipping-positive NSCLC (orphan, sakigake)	25 March 2020
Trintellix (vortioxetine)	Takeda	Depression	20 September 2019
Rozlytrek (entrectinib)	Chugai	NTRK fusion gene-positive advanced/recurrent solid tumors (orphan, sakigake)	18 June 2019
Ultomiris (ravulizumab)	Alexion	Paroxysmal nocturnal hemoglobinuria (orphan)	18 June 2019
Urece (dotinurad)	Fuji Yakuhin	Gout and hyperuricemia	23 January 2020
Vanflyta (quizartinib)	Daiichi Sankyo	relapsed/refractory FLT3-ITD-positive acute myeloid leukemia (orphan)	18 June 2019
Velexbru (tirabrutinib HCl)	Ono	Relapsed/refractory primary CNS lymphoma (orphan)	25 March 2020
Venclexta (venetoclax)	AbbVie	Relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma	20 September 2019
Viltepso (viltolarsen)	Nippon Shinyaku	Duchenne muscular dystrophy with dystrophin gene deficiency amenable to exon 53 skipping therapy (orphan, sakigake, conditional early approval)	25 March 2020
Vonvendi (vonicog alfa)	Shire (Takeda)	Bleeding tendency in von Willebrand disease (orphan)	25 March 2020

Oncology Dominant As Japan Maintains Approvals Pace

Several Global Firsts In Annual Tally

More from Japan

More from Asia